Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;21(1):47-67.
doi: 10.1080/14760584.2022.1997601. Epub 2022 Jan 11.

Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants

Bhaswati Chatterjee  1 , Suman S Thakur  2
Affiliations

Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants

Bhaswati Chatterjee et al. Expert Rev Vaccines. 2022 Jan.

Abstract

Introduction: Appearances of SARS-CoV-2 variants have created havoc and additional challenges for the ongoing vaccination drive against pandemic COVID-19. Interestingly, several vaccine platforms are showing great potential to produce successful vaccines against SARS-CoV-2 and its variants. Billions of COVID-19 vaccine doses have been administered worldwide. Mix-and-Match COVID-19 vaccines involving the mixing of the same platform vaccines and also two different vaccine platforms may provide greater protection against SARS-CoV-2 and its variants. COVID-19 vaccines have become one of the most important tools to mitigate the ongoing pandemic COVID-19.

Areas covered: We describe SARS-Cov-2 variants, their impact on the population, COVID-19 vaccines, diverse vaccine platforms, doses of vaccines, the efficacy of vaccines against SARS-CoV-2 and its variants, mitigation of the COVID-19 transmission- alternatives to vaccines.

Expert opinion: Diverse vaccine platforms may safeguard against ongoing, deadly SARS-CoV-2 and its infectious variants. The efficacies of COVID-19 vaccines are significantly high after the administration of the second dose. Further, it protects individuals including vulnerable patients with co-morbidities from SARS-CoV-2 and its variants. The hospitalizations and deaths of the individuals may be prevented by COVID-19 vaccines.

Keywords: COVID-19; diverse; platforms; sars-cov-2; vaccines; variants.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Vaccine against SARS-CoV-2.
Figure 2.
Figure 2.
Vaccines for COVID-19 are in the emergency use listing (EUL)/ prequalification evaluation process at WHO.
Figure 3.
Figure 3.
Vaccines for COVID-19 under the different phases of the clinical trial.
Figure 4.
Figure 4.
Mode of administration of COVID-19 vaccines.
Figure 5.
Figure 5.
Diverse platform vaccines under clinical trial for COVID-19.
Figure 6.
Figure 6.
Diverse platform vaccines in Pre-clinical trial for COVID-19.
Figure 7.
Figure 7.
Doses of COVID-19 vaccines for immunization against SARS-CoV-2.
See this image and copyright information in PMC

References

    1. Thakur SS. Proteomics and Its Application in Pandemic Diseases. J Proteome Res. 2020;19(11):4215–4218. - PubMed
    1. Krittanawong C, Kumar A, Hahn J.. Cardiovascular risk and complications associated with COVID-19. Am J Cardiovasc Dis. 2020;10(4):479–489. - PMC - PubMed
    1. Apicella M, Campopiano MC, Mantuano MCOVID . 19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782–792. - PMC - PubMed
    1. Chatterjee. B, Thakur SS. ACE2 as potential therapeutic target for pandemic COVID-19. RSC Adv. 2020;10(65):39808–39813. - PMC - PubMed
    1. de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395(10238):1705–1714. - PMC - PubMed

Substances

Supplementary concepts